Allakos (NASDAQ:ALLK) Downgraded by Citizens Jmp to “Hold”

Allakos (NASDAQ:ALLK) was downgraded by analysts at Citizens Jmp from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Allakos Trading Up 9.1 %

ALLK stock opened at $0.26 on Monday. The business’s fifty day moving average price is $1.04 and its 200 day moving average price is $0.90. Allakos has a 12-month low of $0.23 and a 12-month high of $1.69. The company has a market capitalization of $23.04 million, a PE ratio of -0.13 and a beta of 0.86.

Allakos (NASDAQ:ALLK) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. Research analysts predict that Allakos will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Allakos

Institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd purchased a new position in Allakos in the second quarter valued at $25,000. Cubist Systematic Strategies LLC acquired a new stake in Allakos in the 2nd quarter valued at about $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Allakos in the 2nd quarter valued at about $112,000. RBF Capital LLC grew its position in shares of Allakos by 45.9% during the third quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after buying an additional 160,529 shares in the last quarter. Finally, GSA Capital Partners LLP increased its stake in shares of Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after buying an additional 84,750 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.